Drugs / MCARH125
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05431608 | Jun 2022 → Jun 2027 expected | plasma cell myeloma, refractory plasma cell neoplasm | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MCARH125 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05431608 ↗ |
| Modality | Cell therapy | “BCMA-Targeted CAR T Cell MCARH125” NCT05431608 ↗ |